An elected member of the National Academy of Medicine, the Association of American Physicians, and the American Society for Clinical Investigation, Dr. Chin is a world renowned cancer genomic scientist, a frequent speaker in national and international conferences including TEDMed, who has authored or co-authored hundreds of peer-reviewed publications. At Dana-Farber Cancer Institute where she was a professor at Harvard Medical School and a senior associate member at the Broad Institute of MIT and Harvard, Dr. Chin conducted research spanning mouse models of human cancers, cancer genomics, functional genomics and personalized medicine. Outside of her laboratory, Dr. Chin held multiple leadership positions in The Cancer Genome Atlas (TCGA) project in the U.S., including serving on the executive subcommittee and leading the development of Firehose pipeline as co-PI at the Broad Institute. Internationally, Dr. Chin has been active in the International Cancer Genome Consortium since its inception, currently sitting on the ICGC-ARGO Steering Committee and chairing its Phenomics Working Group.
In 2011, Dr. Chin joined MD Anderson Cancer Center as the founding chair of the Department of Genomic Medicine, with a mission to accelerate the translation of scientific advances and democratize the best care to patients outside of academic centers through technologies, data and analytics. As chair, she launched APOLLO (Adaptive Patient-Oriented Longitudinal Learning and Optimization), a workflow platform to facilitate patient-orieinted research, and TRA (Translational Research Accelerator), a big data platform built to integrate longitudinally research and clinical care data at MD Anderson. She also conceptualized and led the development of MD Anderson Oncology Expert Advisor© powered by IBM Watson to demonstrate how AI analytics could be responsibly developed to democratize knowledge for evidence-based care. In 2015, foreseeing the need for a new model to harness real-world health and health-related data, Dr. Chin created the Institute for Health Transformation as the Chief Innovation Officer for Health Affairs at the University of Texas System. She conceived and founded Project DOC (Diabetes Obesity Control) to re-imagine technology-enabled chronic disease management for the vulnerable populations who are unequally burdened. Collaborating with public and private entities across industries, engaging local stakeholders in communities from federally qualified health center to churches, Dr. Chin established an industry-first digitally connected health data and care delivery ecosystem in one of the poorest communities in South Texas to implement REDI (Real-world Education, early Detection and Intervention), a framework that extends the concept of PCHM (Patient-Centered Medical Home) to deliver technology-enabled and data-informed chronic disease management.
A mother of 3 teenagers, Dr. Chin is also an entrepreneur who has founded or co-founded cancer therapeutics, biomarker and AI companies. Apricity Health, her latest initiative aiming to improve access to quality healthcare for patients, is a knowledge company developing digital therapeutics to put world-class subspecialty expertise in the hands of practicing physicians around the world, starting with management of treatment-related toxicities in cancer patients receiving immuno-oncology therapies.